Targeting protein kinase C subtypes in pancreatic cancer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalExpert Review of Anticancer Therapy
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Pancreatic Neoplasms
Protein Kinase C
Enzymes
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Adenosine Triphosphate
Cytokines
PKC-3 protein

Keywords

  • inhibitor
  • pancreatic cancer
  • protein kinase C
  • therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Targeting protein kinase C subtypes in pancreatic cancer. / Storz, Peter.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 4, 01.04.2015, p. 433-438.

Research output: Contribution to journalArticle

@article{470317da289c4fc79fd418d3c243ba75,
title = "Targeting protein kinase C subtypes in pancreatic cancer",
abstract = "In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.",
keywords = "inhibitor, pancreatic cancer, protein kinase C, therapy",
author = "Peter Storz",
year = "2015",
month = "4",
day = "1",
doi = "10.1586/14737140.2015.1003810",
language = "English (US)",
volume = "15",
pages = "433--438",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Targeting protein kinase C subtypes in pancreatic cancer

AU - Storz, Peter

PY - 2015/4/1

Y1 - 2015/4/1

N2 - In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.

AB - In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.

KW - inhibitor

KW - pancreatic cancer

KW - protein kinase C

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84925669194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925669194&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1003810

DO - 10.1586/14737140.2015.1003810

M3 - Article

C2 - 25604078

AN - SCOPUS:84925669194

VL - 15

SP - 433

EP - 438

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -